Saunders exits Bausch + Lomb again, and the timing jolts an eye health company in transition
Brent Saunders has left Bausch + Lomb for a second time, ending a return that lasted less than four years and handing the eye health company a new interim leader just as it is trying to define its next phase. The departure was mutually agreed upon by Saunders and the board, and Thomas Appio, who already serves as CEO of Bausch Health and took on the Bausch + Lomb chair role in August, is now steering the company on an interim basis.
The move lands with unusual force because Saunders had come back to a business with obvious room to grow and framed his return as a reset. His public exit message painted the company as stronger, more focused and better positioned than when he rejoined it. Yet leadership changes of this kind rarely arrive without raising fresh questions about execution, governance and the pace at which a specialty eye care franchise can convert strategy into durable commercial and clinical progress.
The abruptness matters. Evercore ISI analysts described the transition as unexpected given the pipeline projections and commercial targets Bausch + Lomb had already laid out, and Appio’s temporary takeover suggests the decision may not have been anticipated broadly inside the organization either. In a company that depends on stable execution across device, prescription and consumer eye health markets, even a cleanly framed leadership handoff can unsettle investors, partners and employees who are watching for continuity.
A leadership change lands at a company built on long-cycle eye care execution
Bausch + Lomb sits in a part of medicine where product cycles are often long, trust is hard won, and operational discipline can matter as much as headline product launches. Ophthalmology companies have to manage multiple layers at once: regulated products, physician adoption, payer friction, surgical economics and consumer-facing brand awareness. A CEO change does not alter any of those fundamentals overnight, but it can reshape how aggressively a company prioritizes one segment over another and how quickly it pushes programs forward.
Saunders’ tenure was linked to the idea that Bausch + Lomb could be sharpened into a more coherent eye health company with a clearer identity. That kind of reframing often matters in ophthalmology, where businesses may span contact lenses, surgical devices, prescription therapies and over-the-counter products. The commercial challenge is to make those businesses reinforce one another rather than compete for management attention. A leadership reset can either accelerate that integration or expose the gaps that were never fully closed.
Appio’s appointment as interim CEO keeps the company in the hands of a familiar executive. He has led Bausch Health since 2022 and joined Bausch + Lomb’s chair role only recently, which suggests the board is prioritizing continuity over a long search process. Interim leadership can calm a transition if it preserves operational rhythm, but it can also signal that a permanent strategic direction is still being negotiated.
Saunders’ return statement pointed to a company with “a clearer strategy” and “a more robust pipeline.” Those are the exact assets that become most sensitive when a CEO leaves early. A pipeline is not merely a list of assets; it is a set of development bets that depend on capital allocation, trial pacing, regulatory navigation and internal confidence. When the chief executive departs, each of those moving parts becomes easier to scrutinize.
What the board is likely trying to protect: momentum, discipline and investor confidence
For Bausch + Lomb, the practical challenge is not just replacing a well-known executive. It is preserving the appearance and the reality of momentum in a category where confidence is built slowly. Ophthalmology customers and investors alike tend to value consistency because sales cycles, surgeon relationships and development plans are often extended over years rather than quarters.
This is also why analyst reaction matters. When Evercore ISI called the move unexpected, it implicitly flagged a mismatch between the company’s stated growth ambitions and the leadership change that arrived before those ambitions could be fully tested. In corporate terms, that can raise questions about whether the company is rebalancing around performance, personality, or strategy. The board’s language of mutual agreement avoids drama, but it does not remove the operational uncertainty that follows a second exit by the same chief executive.
For a company in eye health, the stakes are especially concrete. Patients do not experience “leadership change” directly, but they do feel the downstream effects if product development slows, commercial priorities shift or internal focus scatters. A company trying to advance a pipeline while defending existing franchises needs a steady hand at the top, because ophthalmology programs often require sustained investment before any benefit reaches clinics, surgical centers or pharmacies.
One sentence captures the shift plainly: Bausch + Lomb now has to execute without the executive who framed its recent strategy.
The near-term question is execution, not rhetoric
Appio’s interim role likely buys time, not certainty. His dual position across Bausch Health and Bausch + Lomb may help the parent and subsidiary stay aligned, but it also concentrates responsibility during a period when the company may need to reassure multiple audiences at once. Shareholders will look for evidence that commercial performance remains on track. Employees will watch for continuity in leadership style and priorities. Clinicians and business partners will watch for whether product and pipeline commitments keep moving at the same pace.
Saunders, for his part, leaves behind a familiar corporate narrative in which a turnaround or repositioning has been declared and then interrupted before the market can fully judge the result. That is often how executive transitions are remembered in biopharma: not as isolated events, but as inflection points that expose whether a strategy was deeply institutionalized or still dependent on one person’s authority.
Bausch + Lomb has not detailed a permanent succession timeline, and the company has not indicated whether the interim arrangement will prompt any change in pipeline priorities or commercial strategy. Until that becomes clear, the most relevant issue is whether the business can maintain confidence in its eye health portfolio while the board settles on its next chief executive. In a sector that depends on steady development, even one unplanned departure can become a test of organizational resilience.